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(6.47-inﬁnity) were calculated or conﬁrmed and compared
among the studies. Variability was explained by the use of
different cut-offs, different reference methods (e.g. cDXA’s
measurement sites) and different subject’s populations.
CONCLUSIONS: Although the results of some studies appear
promising; further reﬁnement of indications, population-speciﬁc
reference databases and studies to determine valid cut-off are
needed before the technology can be successfully introduced into
routine care.
PMS3
A COMPARISON OF CLINICAL EFFICACY OF LEFLUNOMIDE
VS OTHERTHERAPUETIC OPTIONS INTHETREATEMENT OF
RHEUMATOID ARTHRITIS
Rys P1, Kucia K1, Pankiewicz O1, Rogoz A1, Lis J2, Nadzieja-Koziol A1,
Gurda-Duda A1
1HTA Consulting, Krakow, Poland, 2Sanoﬁ-Aventis sp. z o.o,Warszawa,
Poland
OBJECTIVES: The objective of this study was to compare efﬁ-
cacy and safety of leﬂunomide with biological antirheumatic
drugs (adalimumab, etanercept, inﬂiximab, rituximab, anakinra)
in active rheumatoid arthritis. METHODS: Comparison was
based on systematic review, carried out according to guidelines
published by the Cochrane Collaboration and Agency for Tech-
nology Assessment in Poland. The most important medical data-
bases (EMBASE, MEDLINE, CENTRAL) were searched. Two
reviewers independently selected trials, assessed trial quality and
extracted data. No head to head trials were identiﬁed so indirect
comparison using Bucher’s method was performed. RESULTS:
The results of 33 randomized controlled trials were included in
indirect comparison. Leﬂunomide was shown to have better
ACR20 response than anakinra (RR = 1.44 [1.14; 1.81]) but no
signiﬁcant differences in ACR response were found in compari-
sons with other drugs. Comparisons of HAQ disability scores
indicate than leﬂunomide reduces disability better than adali-
mumab (WMD = -0.15; [-0.29; -0.01]), inﬂiximab (WMD =
-0.35 [-0.50; -0.20]), anakinra (WMD = -0.47 [-0.69; -0.25]),
rituximab (WMD = -0.38 [-0.59; -0.17]), but not etanercept
(WMD = -0.18 [-0.37; 0.01]). Radiographic improvement was
better in comparison with anakinra (WMD = -2.99 [-5.82;
-0.16]) and rituximab (WMD = -4.05 [-6.67; -1.43]) whereas
worse in comparison with adalimumab (WMD = 2.67 [0.87;
4.47]), etanercept (WMD = 1.75 [0.01; 3.49]) and inﬂiximab
(WMD = 2.06 [0.42; 3.70]). Leﬂunomid signiﬁcantly increases
the risk of treatment discontinuation due to the adverse events in
comparison with etanercept (RR = 3.50 [1.55; 7.88]). No signiﬁ-
cant differences in safety outcomes were noted between leﬂuno-
mid and other drugs. CONCLUSIONS: Indirect comparisons
indicate similar efﬁcacy of leﬂunomid, adalimumab, etanercept,
inﬂiximab or rituximab. Leﬂunomide seems to be more effective
than anakinra. Safety proﬁle of leﬂunomide is worse in compari-
son with etanercept, whereas in comparison with other analyzed
drugs no differences were found.
PMS4
COST-EFFECTIVENESS ANALYSIS OF LEFLUNOMIDE AS A
TREATMENT FOR RHEUMATOID ARTHRITIS IN MEXICO
Carlos-Rivera F1,Aguirre-Granados A1, Manterola SOMC2
1R A C Salud Consultores, S.A. de C.V, Mexico DF, Mexico,
2Economía de la Salud. Sanoﬁ-Aventis, Mexico City, Mexico
OBJECTIVES: To estimate the cost-effectiveness relationship of
leﬂunomide compared to inﬂiximab, etanercept and adalimumab
for the treatment of patients with rheumatoid arthritis (RA) with
suboptimal response despite methotrexate (MTX) monotherapy.
METHODS: Time horizon was 24 weeks. Efﬁcacy data was
obtained from systematic review of published literature. The
model compares four groups: leﬂunomide, inﬂiximab, etanercept
and adalimumab, all in combination with MTX, under the per-
spective of Public Health Sector in Mexico. We included direct
costs of medications during 24 weeks and costs associated with
therapeutic failure due to adverse events or lack of efﬁcacy. In
those cases, we calculated initial treatment costs during 8 weeks,
and after treatment changed, it was estimated an average cost of
biological therapy for the 16 remaining weeks. The effectiveness
measure was the response rate according to the American College
of Rheumatology criteria (ACR). The analysis was conducted
using Tree Age Pro Suit 2006. RESULTS: The proportion of
patients reaching an ACR20 response was 50% for leﬂunomide,
53% for inﬂiximab, 61.6% for adalimumab and 67.9% for
etanercept. The expected costs of 24 weeks of treatment were
€891.2, €4274.5, €5054.5 and €4072.3 for leﬂunomide, inﬂix-
imab, adalimumab and etanercept, respectively. The cost per
patient with ACR20 improvement was €1781.8 for leﬂunomide,
€8205.8 for adalimumab, €8069.9 for inﬂiximab and €5996.7
for etanercept. The average cost per patient reaching an ACR50
or ACR70 response was also much lower for leﬂunomide
(€ 3,248.7, €8,999.2) than for the biological agents: etanercept
(€ 9492.6, €23,424.6), adalimumab (€ 12,290.4, €23,646.5),
inﬂiximab (€14,726.1, €40,349.5). CONCLUSIONS: Leﬂuno-
mide added to MTX is a cost-effective strategy compared to
inﬂiximab, adalimumab and etanercept, each one added to MTX
in patients with suboptimal response to MTX monotherapy.
Therefore, we recommend the use of leﬂunomide for patients
with refractory RA with suboptimal response to MTX, before
using a biological agent.
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OBJECTIVES: To assess the estimated prevalence of ﬁbromyal-
gia syndrome (FM) among the adult population in the general
population, in Germany, using the London Fibromyalgia
Epidemiology Study—Screening Questionnaire (LFESSQ) and
American College of Rheumatology (ACR) classiﬁcation criteria.
METHODS: Every patients going to visit the rheumatologist in
Munchen hospital during a 30-days period, were interviewed
using the validated LFESSQ (4 items) with two additional ques-
tions on fatigue (LFESSQ 6 items), and examined to conﬁrm the
diagnostic of FM using ACR classiﬁcation criteria. The screening
questionnaire was also administered to a representative commu-
nity sample more than 15 years old, selected by the quota
method. The prevalence of FM was estimated in the general
population, applying the predictive positive value observed in
rheumatology consultation, to the positive screens, RESULTS:
A total of 52.6% patients interviewed in the rheumatology
department were screened positive for chronic widespread pain
(LFESSQ 4), 42.7% for widespread pain and fatigue (LFESSQ 6),
16.4%[15.8–16.9] were conﬁrmed FM cases. Based on positive
screens for chronic widespread pain and LFESSQ 4, the preva-
lence of FM in general population, is 5.8 % (95% IC: [4.3–7.2];
7.5% in females and in 3.8% males respectively). If fatigue is
added, the prevalence is 3.2 % (95% IC: [2.1–4.3] ; 3.9% in
females and 2.5% in males respectively). Prevalence rises with
age until the age group 75–84 years old. FM sufferers are females
wit an average age of 53.5 years old (SD: 12.4). CONCLU-
SIONS: Our ﬁndings are slightly higher than those obtained in
our study in France, Spain and Portugal, and those published in
Canada, US or Spain, probably due to the different methodolo-
gies and populations used. Symptoms of pain as fatigue must be
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